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Abstract
Background: Although anti-asthma medications are amongst those most frequently under or over prescribed it is
generally accepted that prescriptions for such agents can be used as a proxy for disease prevalence. The aims of
this study were to estimate prevalence and incidence of childhood asthma in a representative Italian area by
analysing three years of anti-asthmatic prescriptions and hospitalizations of subjects with chronic or first time
treatment, and to underline appropriateness of therapeutic choices.
Methods: The analysis involved prescriptions given to 6-17 year olds between 2003 and 2005 in Italy’s Lombardy
Region. The youths were classified as potential asthmatics, based on the different degree of drug utilization:
occasional, low or high users, and grouped as ‘new onset’ or ‘chronic’ cases based on the duration of therapy
dispensed. The analysis of prescriptions and hospitalization rate of these groups provided an estimate of the 2005
asthma prevalence and incidence and allowed an estimation of the level of appropriateness of treatments.
Results: During 2005, the estimated incidence of potential asthmatics was 0.8% and the estimated prevalence was
3.5%. When viewed retrospectively for two years, records showed that 47% of potential asthmatics received
prescriptions also during 2004 and 30% also during 2003. During the three years considered, 7.5%, 2.8%, and 1.5%
of high, low, and occasional users, respectively, were hospitalized for asthma. The most important
inappropriateness found was the prescription of long acting beta adrenergics as first time treatment.
Conclusions: This study allowed a proxy of asthma incidence, prevalence, and severity. The analyses highlighted a
low compliance with the guidelines, suggesting that educational interventions are needed to obtain a more
rational management of childhood asthma, especially in subjects starting therapy.
Keywords: asthma, anti-asthmatic drugs, children and adolescents, pharmacoepidemiology, prescription, drug
utilization
Background
Asthma is one of the leading chronic childhood diseases,
and its prevalence in Italy remained largely stable
between 1995 and 2002 (9%) [1]. Prior to school age
many children experience recurrent episodes of wheez-
ing and cough. These symptoms are frequently transi-
ent, and 60% of preschoolers are asymptomatic by age
six [2,3]. For this reason, children have a higher overall
prevalence of anti-asthmatic prescriptions compared to
adolescents. Regarding asthma therapy, international
guidelines recommend inhaled corticosteroids (ICS) for
long-term control of persistent asthma and short acting
b2 adrenergic (SABA), such as salbutamol, as first
choice in acute attacks [4-6]. In particular, the pharma-
cological therapy for long term control is recommended
in a stepwise approach, based on asthma severity.
Although adherence to guidelines reduces the number
of outpatient and emergency department visits [7],
guidelines seem far from being routinely applied in clin-
ical practice. The main inadequacy seems to be the use
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infections [8] and under-prescribed for preventive ther-
apy between asthma attacks. Another inadequacy is the
use of long acting beta adrenergics (LABAs). Guidelines
suggest increasing the dose of ICS before adding
LABAs. The FDA recommends the use of LABAs with-
out an ICS for the shortest amount of time required to
achieve control of symptoms, because of the increased
risk of asthma exacerbations, hospitalizations, and death
[9]. The aims of this study were to estimate prevalence
and incidence of childhood asthma in a representative
Italian area by analysing three years of anti-asthmatic
prescriptions and hospitalizations of subjects with
chronic or first time treatment, and to underline appro-
priateness of therapeutic choices.
Methods
The analysis involved all paediatric prescriptions reim-
bursed by the National Health Service (NHS) and dis-
pensed by the retail pharmacies of 15 Local Health Units
(LHUs) in the Lombardy Region between January 2003
and December 2005. The database stores all community
(i.e. outside hospital) prescriptions reimbursed by the
NHS and issued to individuals living in the Lombardy
Region. Prescriptions issued to the entire paediatric
population are fully reimbursed by the NHS in Italy. The
structure of the database has been described in detail
elsewhere [10]. Although it is an administrative database,
it has shown high accuracy in other studies [11].
Data were managed and analysed using an anonymous
patient code. The approval by the ethics committee is
not required in Italy for this kind of study.
The study population was composed of 1,016,683 chil-
dren and adolescents 6-17 years old, male/female ratio
1.1, living in the Lombardy Region. The study sample
represented 15% of the overall Italian paediatric
population.
In 2005 in the Lombardy region there were 1165 pri-
mary care paediatricians and 6791 general practitioners.
Anti-asthmatics were classified as drugs belonging to
the R03 main therapeutic group of the Anatomical
Therapeutic Chemical classification system (ATC).
Prevalence data by age and sex were calculated as
number of children to whom anti-asthmatic drugs were
dispensed per 100 inhabitants.
Definition of potential asthmatics (PA)
Potential asthmatics (PA) were considered to be subjects
≥ 6 years old receiving, during 2005, at least one pack-
age (canister or box) of the active substances listed in
Table 1.
Subjects receiving exclusively anti-asthmatic drugs in
nebulised formulations (appropriate under age 2) or
LTRA as exclusive therapy (prescribed for allergic
rhinitis control), without any other anti-asthmatic drug,
were not included.
The strategy (based on anti-asthmatic prescriptions) for
PA identification used in this study has been previously
validated [12] by the comparison with paediatricians’
diagnosis of the same subjects identified as PA. Sensitiv-
ity was 0.91 [95% confidence interval (95% CI): 0.67-
1.00], whereas specificity was 0.98 (95% CI: 0.96-1.00).
Degree of consumption
PA patients were divided into three groups, based on
number of packages (canister or box) received during
2005: A) “occasional users”, subjects receiving only one
p a c k a g e( i . e .as i n g l ec o u r s eo ft h e r a p y ) ;B )“low users”,
subjects receiving 2-4 packages; C) “high users”, subjects
receiving 5 or more packages. The threshold of five
packages was chosen because it represents the 90th per-
centile in distribution of frequency of treated children
by number of packages.
’Chronic’ and ‘new onset’ cases
In order to evaluate the extent of chronic treatment, peo-
ple who received anti-asthmatic drug prescriptions also
during 2003 and 2004 were identified. Moreover, patients
with new onset asthma were described as: 1) not having
received anti-asthmatic therapy during the previous two
years (2003 and 2004) and 2) not having been hospita-
lized for asthma during the 2003-2005 period. A compar-
ison of prescription profiles between chronically treated
youths (three year persistence of therapy) and youths
with new onset asthma was performed. A chi-square test
(c
2) was performed between groups in order to evaluate
statistically significant differences.
Hospitalizations
Rate of hospitalization for asthma (corresponding to the
diagnosis code 493 of the International Classification of
Table 1 Anti-asthmatic agents
Active substances Formulation
SABA (Salbutamol, fenoterol);
ICS (beclomethasone, fluticasone,
flunisolide, budesonide);
LABA (formeterol, salmeterol, fixed
association budesonide/formoterol, fixed
association fluticasone/salmeterol);
Metered dose inhalers Dry
powder inhalers
Chromones (Cromolyn Sodium,
Nedocromil Sodium);
Anticholinergics (ipratropium bromide,
oxitropium bromide).
Theophyllines;
LTRA (montelukast, zaphirlukast), not as
exclusive therapy;
Oral
Steroids, not as exclusive therapy.
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estimated for the period from January 2003 to Decem-
ber 2005 using hospital discharge forms.
Differences between the LHUs
Estimation of the prevalence of asthma at LHU level was
calculated as the number of PA per 100 children aged 6-
17 who were listed under that particular LHU. Estima-
tion of the incidence of asthma at LHU level was calcu-
lated as the number of PA youths who received an anti-
asthmatic prescription for the first time in 2005 per 100
children aged 6-17 who were listed under that particular
LHU. The relationship between incidence and preva-
lence and between prevalence and hospitalization rates
by local health unit was investigated using the nonpara-
metric Spearman rank correlation test. Finally, a logistic
regression analysis was performed in order to identify
risk factors for asthma by evaluating the association
between drug prescription and gender, LHU of resi-
dence, kind of physician in charge of the patient (pae-
diatrician vs. general practitioner), and physician gender.
Concerning the LHU of residence, Milan was chosen as
r e f e r e n c e ,s i n c eap r e v i o u ss t u d yf o u n di th a dt h eL H U
with the lowest prevalence of drug prescriptions [11].
The odds ratio (OR) and relative 95% confidence inter-
val (CI) between the groups were calculated. Statistical
analysis was performed using SAS software, version 9.1
(SAS Inc., Cary, NC, USA). A p value < 0.05 was consid-
ered to be statistically significant.
Results
Prevalence and incidence of potential asthmatics (PA)
Potential asthmatics were 35,399 (3.5% of the 6-17 year
old population). The median age, interquartile range
(IQR), and boy/girl ratio were, respectively 11, 9-14, and
1.7. The occasional users were 9,482 (27% of the PA), the
low users were 16,438 (46%), and the high users were
9,479 (27%). During the three years considered, 2,456 chil-
dren and adolescents were hospitalized at least once for
asthma. Among these subjects, 1318 (54%) were identified
as PA, whereas 1138 (46%) did not receive any anti-asth-
matic drugs during 2005 or received nebulised formulation
or montelukast as exclusive treatment. The percentage of
PA children hospitalized for asthma ranged from 1.5% in
the occasional users to 2.8% in low users, and 7.5%, in the
high users (χ2
t =4 8 7; p < 0.001), while the hospitalization
rate for other reasons was constant in the three groups. In
all, 16,629 children and adolescents (47% of the subjects
defined PA) received age-appropriate anti-asthmatic pre-
scriptions also during 2004 and 10,712 (30%) during 2004
and 2003 (Table 2). The median age of these chronically
treated patients was 11 (IQR = 8-14), with a higher preva-
lence in boys. Most children were cared for by a family
paediatrician (Paediatrician/GP ratio = 1.2). The percen-
tage of chronically treated patients differed between the
three groups of users, and ranged from 45% in occasional
users to 87% in high users. (χ2
t = 3636; p < 0.001).
A total of 8,058 subjects (23% of the subjects defined
as PA) were diagnosed as potential asthmatics for the
first time during 2005 (incidence 0.8%). The median age
was 12 (IQR = 9-15), and the boy/girl ratio was 1.4. The
majority of children were cared for by a general practi-
tioner (Paediatrician/GP ratio = 0.7).
Prescription profiles
In all, 66% of the PA subjects were treated with SABA (1/
5 of these received SABAs exclusively), 36% with ICS
alone, 45% with ICS and other anti asthmatics (23% with
ICS and LAB A), and 6% with other anti asthmatics. 95%
of PA subjects received inhaled formulations and 16% of
children and adolescents also received oral formulations
(theophyllines, LTRA, or steroids). The drug most com-
monly prescribed was salbutamol (55% of subjects), fol-
lowed by fluticasone (29%), beclomethasone, and
salmeterol/fluticasone in fixed combination (both 23%).
6.7% received systemic steroids, with differences between
groups, with the high users having nearly three times a
greater chance of receiving systemic steroids compared
to occasional users (11.5% vs. 4.0%, respectively; c
2 =
430; p < 0.001). The comparison between prescription
profiles of chronically treated youths and youths with
new onset asthma is reported in Table 2. The percentage
of youths receiving at least one SABA prescription was
similar in chronically treated users and in new users (56%
Table 2 Percentage of children and adolescents
identified as new onset or chronic asthmatics and their
anti-asthma therapy
DRUG CLASSES NEW ONSET CHRONIC ASTHMA
8,058 10,712
Rescue Medications
SABA 5,023 (62) 7,121 (56)
SABA exclusively
a 1,933 (24) 1,138 (11)
Systemic steroids 391 (5) 919 (9)
Controller Medications
ICS 4,876 (44) 8,569 (56)
alone
b 2,661 (33) 3,176 (30)
ICS+LABA 1,884(7) 4,579 (19)
ICS+LTRA 267 (3) 1,181 (11)
ICS+Others
c 902 (11) 2,848 (27)
no ICS 610 (8) 643 (6)
LABA 130 (2) 82 (0.3)
a without other anti-asthmatic prescriptions
b without other controller drug prescriptions
c Others = not ICS, not SABA, not LABA, not LTRA
data are expressed as number of subjects (% of each population)
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SABA as exclusive therapy was higher in new users than
in chronically treated users (24% versus 11%). The per-
centage of children and adolescents receiving ICS alone
was similar (30% of chronic versus 33% of new users). On
the contrary, new users receiving ICS with other anti-
asthmatics (LABA, LTRA, or others) were fewer than
chronically treated patients. Furthermore, the percentage
of children with at least one prescription of systemic ster-
oids was higher in those chronically treated than in new
users (9 versus 5%).
’New onset’ cases and first drugs received
In all, 45% of the youths with new onset asthma
received only one medication package (occasional users),
while only 9% resulted as high users (Table 3). In all, 7%
of new users received LABA associated with ICS and 2%
without ICS (Table 2). Salbutamol was the drug most
commonly given as the first anti-asthmatic prescription
(45% of youths with new onset asthma), followed by
beclomethasone (17%), fluticasone (14%), and salme-
terol/fluticasone (13%). In all, 20% of the patients with
new onset asthma received 2 or more drugs as their
first prescription (mainly salbutamol and beclometha-
sone). A total of 614 youths (8% of the new onsets)
received only salmeterol and fluticasone in fixed combi-
nation as their first and unique prescription (occasional
users). Moreover, 66 children received only one pre-
scription of LABA without any other anti-asthmatic.
Differences between the LHUs
Large differences were found in prevalence of PA rates
between different LHUs, ranging from 2.5% in Pavia to
5.1% in Mantova (Figure 1). Differences in prevalence of
asthma persist also after adjusting for gender and age. A
similar geographical distribution was found for the rate
of chronically treated youths, with a prevalence ranging
from 0.7% in Pavia to 1.8% in Mantova. A statistically
significant correlation between rank distributions at
LHU level of the total PA and chronically treated youth
prevalence rate was found (rs =0 . 9 2 ;p = 0.0006). Small
differences in the incidence of asthma (percentage of
youths with new onset asthma) between LHUs were
found; these ranged from 0.59% in Pavia to 0.94% in
Como. No correlation was found between the rank dis-
tribution at LHU level of incidence and prevalence of
PA, nor between incidence and percentage of chroni-
cally treated youths. Moreover, no correlation was found
between rank distribution at LHU level of the PA preva-
lence rates and hospitalizations during the 2003-2005
period (ranging from 0.1% in Bergamo to 0.4% in Lodi).
Being male (OR 1.67, 95% CI 1.64-1.71) and living in
Mantova (OR 1.91, 95% CI 1.80-2.03) were the factors
associated with the highest chance of being identified as
a PA subject. On the contrary, youths living in Pavia
had a lower chance of being asthmatic compared with
children living in Milan (OR 0.91; 95%CI 0.85-0.97).
Discussion
It was possible to define the severity of asthma in chil-
dren and adolescents 6-17 year old based on the quan-
tity and quality of the therapy by using a database that
stores all community prescriptions of anti-asthmatic
drugs.
The main finding of this study is the inappropriate-
ness of drug prescriptions, especially in the prescription
of LABAs without steroids. In particular, it seems that
t h es u b j e c t sw h oa r en e wc a s e so fa s t h m aa r et h em o s t
inappropriately treated: 38% does not receive SABA, 8%
does not receive ICS, 2% receives LABA alone, and 23%
receives the association ICS+LABA.
Strengths and limits
Many studies describing the actual use of asthma medi-
cation in children show a wide variability in treatment,
reporting an over-use in children without asthma and
an under-use in children with doctor-diagnosed asthma
[13-20]. There has therefore been a debate on whether
anti-asthmatic drug utilization studies are a good proxy
for the disease or not [21,22]. However, the strategy
applied in this study, which is similar to those in other
studies [13,19,23,24], has been validated in identifying
potentially asthmatic patients [12]. The limits of this
study are the absence of details on prescriptions (i.e.
d i a g n o s i sa n dd o s e )a n dt h ef a c tt h a tt h eL o m b a r d y
Region is the top Italian region according to the socio-
demographic and economic national profile and may
thus not be fully representative of other Italian settings
Table 3 Prescriptions to new onset asthmatic children
and adolescents
DRUG CLASSES Occasional Low High Total
3,621 3,752 685 8,058
Rescue Medications
SABA 1,986 (55) 2,479 (66) 558 (81) 5,023 (62)
SABA exclusively 1,529 (42) 395 (10) 9 (1.3) 1,933 (24)
not receiving SABA 1,635 (45) 1,273 (34) 127 (19) 3,035 (38)
Systemic steroids 127 (3.5) 196 (5) 68 (10) 391 (5)
Controller Medications
ICS 1,368 (38) 2,874 (77) 634 (92) 4,876 (61)
ICS alone 754 (21) 1,703 (45) 204 (30) 2,661 (33)
ICS+LABA 614 (17) 941 (25) 329 (48) 1,884 (23)
ICS+LTRA 0 118 (3) 149 (22) 267 (1)
ICS+Others 0 584 (16) 318 (46) 902 (11)
No ICS 267 (7.4) 304 (8) 39 (6) 610 (7.6)
LABA alone 66 (1.8) 64 (1.7) 0 130 (1.6)
data are expressed as number of subjects (% of each population)
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m a yb ed i f f e r e n t .H o w e v e r ,t h el a r g es i z eo ft h es t u d i e d
population made the data suitable for studying the
rational use of drugs in paediatric asthma and other dis-
eases [11]. Moreover, prescriptions issued to the entire
paediatric population are fully reimbursed by the NHS
in Italy and this allows the study of the whole
population.
Estimation of asthma prevalence and incidence in
Lombardy
The first criteria, chosen with the aim to identify poten-
tially asthmatic subjects, was age ≥ 6 years because only
in school-aged children is it possible to diagnose asthma
i nar e l i a b l em a n n e r[ 2 , 3 ] .T h eo t h e rc r i t e r i ai n v o l v e d
the prescription of age-appropriate formulations, and
the use of nebulizers was therefore excluded. LTRA as
monotherapy was excluded because montelukast alone
is prescribed almost exclusively for allergic rhinitis con-
t r o l .U s i n gt h e s ec r i t e r i a ,a3 . 5 %a s t h m ap r e v a l e n c ew a s
estimated. This prevalence is similar to that in a pre-
vious report on the population of Lecco’sL H U ,i n
which the prevalence of PA in 2003 was 3.8% [25] and
is consistent with the prevalence estimated in young Ita-
lian adults [26]. It is possible that the prevalence of
asthma was overestimated in the SIDRIA survey [1]
since the reliability of parent-reported asthma or
asthma-like symptoms, as a measure of asthma preva-
lence, is questionable. The classification of the popula-
tion based on the number of anti-asthmatic packages
received (high, low and occasional users) during 2005
seems reliable in estimating severity, since the percen-
tage of hospitalizations for asthma increased from occa-
sional to high user groups. Among the 2456 children
and adolescents who underwent hospitalization for
asthma once, only 54% were treated with age-appropri-
ate formulations of anti-asthmatics, while 46% did not
receive any anti-asthmatic treatment or received nebu-
lised formulation or montelukast as exclusive treatment.
The fact that nearly half of children and adolescents
hospitalized for asthma at least once during the three
year period did not receive adequate therapy for asthma,
a finding consistent with other studies [15,16], may also
be due to an error in the diagnosis occurring at the
Figure 1 Prevalence of R03 prescriptions in potential asthmatic children and adolescents in the 15 LHUs in the Lombardy region
during 2005.
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Page 5 of 8time of hospitalization. However, even taking into
account the 1138 youths that were hospitalized, but who
did not receive an appropriate anti-asthma drug therapy
during 2005, and the 20,158 youths who received anti-
asthma treatment during 2004, but not during 2005, the
overall percentage of children having asthma episodes
during 2005 or who had had episodes in the previous 12
months can be estimated at 5.6%, which is very similar
to the data collected by the SIDRIA survey concerning
“wheezing during the past 12 months”.T h i sf i n d i n g
seems to support the hypothesis that an overestimation
o ft h ea s t h m ap r e v a l e n c ei nt h eS I D R I As u r v e yd o e s
exist when “lifetime asthma” is reported by the parents
[1].
The incidence of asthma in the Lombardy region dur-
ing 2005, estimated in 6-17 year old subjects, was 0.8%
(Table 2), lower than the incidence in Norway (1.5% in
the population of 2-29 year olds) [23] and in the Neth-
erlands (4.3% in the 0-9 year old population) [20]. The
differences are probably due to the different age groups;
preschoolers in particular may increase the incidence in
Norway and in the Netherlands [23,20]. As for the inci-
dence, in the Lombardy region the prevalence was also
lower (3.5%) than in Norway (5.1%) [23] and the Neth-
erlands (8.1%) [20], probably for the same reason.
The ‘chronic’ and ‘new onset’ cases and
inappropriateness of treatments
A different prescribing pattern emerged when compar-
ing youths receiving chronic asthma treatment with
youths with new onset asthma receiving treatment for
the first time (Table 2). The fact that 24% of the new
users received SABA exclusively, versus 11% of chronic
users, was expected. The fact that 44% of new users
received ICS as unique controller therapy, versus 56% of
the chronically treated patients, was also expected.
Moreover, chronically treated subjects more commonly
received ICS+ LABA than new users, as guidelines sug-
gest. However, the finding that high numbers of new
users received LABA alone or LABA+ICS (2 and 7%,
respectively), a second line therapy that should be used
in children with moderate-severe asthma who do not
benefit from ICS alone [4-6], is actually raising some
concerns.
This inappropriate use of LABA as initial therapy was
also reported for a US paediatric population [27]. In
steroid-naïve subjects, the combination of ICS and
LABA did not significantly reduce the risk of exacerba-
tions requiring rescue oral corticosteroids compared to
the use of ICS alone with a similar dose [28]. Even in
children already under ICS therapy, it has been reported
that the addition of LABA is not associated with a sig-
nificant reduction in the rate of exacerbations [29]. In a
recent article [30], percentages of LABA (mis)utilization
similar to this study were reported during 2005 in Eng-
land. Although the use of LABA alone is not rational,
the article reported an improvement of adherence to
guidelines from 2000 to 2005, with a decrease of use of
LABA alone and an increase of the LABA+ICS associa-
tion [30]. In Table 3 the new onset users are grouped
based on number of packages received, and more inade-
quacies are made evident: 38% of new users did not
receive a SABA during the one year observation period
and, looking at the first anti-asthmatic drug prescrip-
tions given to the new cases of asthma, more than half
of the subjects did not receive salbutamol. Nearly 20%
of high users did not receive any SABA prescription.
Most of them received ICS+other controller drugs. In
all, 680 children and adolescents, 8% of subjects suffer-
ing from new onset asthma, were treated the first, and
only, time (occasional users) with LABA alone (1% of
new users) or with LABA associated with ICS (8% of
new users).
Prescribing differences in the 15 LHUs
Some differences between LHUs in the Lombardy region
were found in the prevalence of anti-asthmatic prescrip-
tions and the rate of PA seems to be higher in the
south-eastern part of the region (Figure 1). These differ-
ences might be due to different factors: differences in
prescribing attitudes (Brescia also has a high prevalence
of prescription of drugs other than anti-asthmatics [11],
and differences in socio-economic status or disease trig-
g e r s ,i . e .a i rp o l l u t i o n( B r e s c i aa n dM a n t o v aa r et h e
areas with the highest prevalence of anti-asthmatic pre-
scriptions also in the adult population). Epidemiological
studies estimated a prevalence of asthma of 10% both in
Milan [31] and in Brescia [15]. On the contrary, the pre-
valence of asthma medications differed between the two
LHUs (2.7% in Milan and 4.2% in Brescia). However, it
should be noted that in Brescia the prevalence of
asthma diagnosed by physicians was 10.2%, but only
41% of children were under therapy when the survey
was performed [15]. Hence, the prevalence of anti-asth-
matic prescriptions in Brescia found in this study (4.2%)
is consistent with the data already published [15], sug-
gesting that the model used in this study may be valid
in measuring asthma prevalence, taking into considera-
tion the under-treatment of asthma. The greatest gap
between prevalence of drug prescriptions and asthma
prevalence was observed in Milan, and it is possible that
in this LHU a higher percentage of under-treatment or
an over estimation of disease estimated by questionnaire
was present [31]. It is interesting to note that the inci-
dence of asthma was not correlated with prevalence,
and that a greater percentage of children needing a first
time drug treatment was found in LHUs with a signifi-
cantly lower percentage of chronically treated youths.
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prevalence of chronically treated youths correlated with
the rate of hospitalisation.
Conclusions
In conclusion, the analysis of drug prescriptions in chil-
dren receiving asthma treatment highlighted a low com-
pliance with the international guidelines, in particular in
children treated with anti-asthmatics for the first time
with LABA alone, raising questions on appropriateness
of therapeutic choices. A further dynamic study will
hopefully reveal modifications in therapeutic choices, as
occurred in England [30].
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